Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | AKT2 | P31751 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.37 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6420457 | 0.87 | CYP3A4 (0.39) | CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL23716100 | 0.86 | S1PR3 (0.45) | CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11538609 | 0.80 | SLC6A2 (0.50) | CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3828644 | 0.77 | PIK3CD (0.43) | CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4165718 | 0.77 | PIK3CD (0.43) | CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13567642 | 0.77 | PIK3CD (0.43) | CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL751365 | 0.77 | SMN1; SMN2 (0.53) | CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3386704 | 0.77 | AKT2 (0.41) | DPP4F2AKT2IDO1TDO2 | |
| SCHEMBL22927815 | 0.77 | DPP4 (0.38) | DPP4F2AKT2 | |
| SCHEMBL29908263 | 0.77 | DPP4 (0.38) | DPP4F2AKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415480-B2 | Thiazolidine carboxamide derivatives as modulators of the prostaglandin F receptor | MERCK SERONO SA (CH) | 2013-04-09 | — | — | US | disclosed |
| US-8415480-B2 | Thiazolidine carboxamide derivatives as modulators of the prostaglandin F receptor | MERCK SERONO SA (CH) | 2013-04-09 | — | — | US | disclosed |
| US-8415480-B2 | Thiazolidine carboxamide derivatives as modulators of the prostaglandin F receptor | MERCK SERONO SA (CH) | 2013-04-09 | — | — | US | disclosed |
| EP-1487442-B1 | THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR | MERCK SERONO SA (CH) | 2010-12-01 | — | — | EP | disclosed |
| EP-1487442-B1 | THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR | MERCK SERONO SA (CH) | 2010-12-01 | — | — | EP | disclosed |
| US-20090215749-A9 | THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR | LABORATOIRES SERONO S.A. (CH) | 2009-08-27 | — | — | US | disclosed |
| US-20090215749-A9 | THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR | LABORATOIRES SERONO S.A. (CH) | 2009-08-27 | — | — | US | disclosed |
| US-20090215749-A9 | THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR | LABORATOIRES SERONO S.A. (CH) | 2009-08-27 | — | — | US | disclosed |
| CN-100484524-C | Thiazolidine carboxamide derivatives as modulators of the prostaglandin receptor | APPLIED RESEARCH SYSTEMS (CH) | 2009-05-06 | — | — | CN | disclosed |
| US-20080255094-A1 | THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR | LABORATOIRES SERONO S.A. (CH) | 2008-10-16 | — | — | US | disclosed |
| US-20080255094-A1 | THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR | LABORATOIRES SERONO S.A. (CH) | 2008-10-16 | — | — | US | disclosed |
| US-20080255094-A1 | THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR | LABORATOIRES SERONO S.A. (CH) | 2008-10-16 | — | — | US | disclosed |
| US-20050215605-A1 | Thiazolidine carboxamide derivatives as modulators of the prostaglandin f receptor | MERCK SERONO SA (CH) | 2005-09-29 | — | — | US | disclosed |
| CN-1655780-A | Thiazolidine carboxamide derivatives as modulators of the prostaglandin f receptor | APPLIED RESEARCH SYSTEMS (AN) | 2005-08-17 | — | — | CN | disclosed |
| EP-1487442-A1 | THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR | Applied Research Systems ARS Holding N.V. (AN) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003082278-A1 | THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215749-A9 | THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR | PTGER4, PTGER2, PTGER1 | CYP3A4 583/4885CYP2D6 305/4885SLC6A2 4171/4885 |
| US-20080255094-A1 | THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR | PTGER4, PTGER2, PTGER1 | CYP3A4 583/4885CYP2D6 305/4885SLC6A2 4171/4885 |
| US-20050215605-A1 | Thiazolidine carboxamide derivatives as modulators of the prostaglandin f receptor | TBXA2R, CNR2, PTGDR | CYP3A4 1179/4885CYP2D6 475/4885SLC6A2 3464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.